Anti-Human TIM-3 Recombinant Antibody scFv Fragment (mAb15) (CAT#: TAB-666CT-S(P))

Figure 1 show graphs demonstrating that TIM-3 inhibition stimulates expression of DC co-stimulatory molecules and cytokine release by DCs.

Following LPS activation, DCs were treated with no antibody, a mIgG1 isotype control, a commercially available anti-TIM-3 antibody (F38-2E2) or antibodies. Co-stimulatory molecules or cytokines were measured on Day 4 post-LPS activation.

Figure 2 show graphs demonstrating release of IL-1β, TNFα and IL-6 from macrophages stimulated by HMGB-1 following treatment with antibodies.

Antibodies were the commercially available anti-TIM-3 antibody, F38-2E2, and anti-TIM-3 antibody mAb15. mIgG1 served as an isotype negative control antibody.

Figure 3 shows a graph demonstrating a dose curve of release of TNFα from macrophages stimulated by HMGB-1 following treatment with different doses of antibodies.

Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles) and anti-TIM-3 antibody mAb15 (squares).

Figure 4 show graphs demonstrating dose curve of release of IL-1β from macrophages stimulated by LPS following treatment with different doses of antibodies.

Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (squares) and anti-LILRB2 (clone 287219) (inverted triangles). mIgG1 isotype (diamonds) and no antibody (triangles) served as a negative control. Data were collected at 24 hr, 48 hr, and 3 days post-treatment as indicated.

Figure 5 shows mixed lymphocyte reaction on day 1 or day 7 following treatment with F38-2E2, mAb15 or an isotype control.

Supernatants were assessed for their expression of IL-1β, TNFα and IFN-γ at the time points indicated.